Multiple sclerosis can be inhibited or reversed using a novel gene therapy technique that stops the disease’s immune response in mouse models, University of Florida Health researchers have found.
By combining a brain-protein gene and an existing medication, the researchers were able to prevent the mouse version of multiple sclerosis. Likewise, the treatments produced near-complete remission in the animal models. The findings, which researchers said have significant potential for treating multiple sclerosis and other autoimmune disorders, are published today (Sept. 21) in the journal Molecular Therapy.
Multiple sclerosis affects about 2.3 million people worldwide and is the most common neurological disease in young adults. The incurable disorder starts when the immune system attacks the myelin sheath surrounding nerve fibers, making them misfire and leading to problems with muscle weakness, vision, speech and muscle coordination.
The researchers used a harmless virus, known as an adeno-associated virus, to deliver a gene responsible for a brain protein into the livers of the mouse models. The virus sparked production of so-called regulatory T cells, which suppress the immune system attack that defines multiple sclerosis. The gene was targeted to the liver because it has the ability to induce immune tolerance.
“Using a clinically tested gene therapy platform, we are able to induce very specific regulatory cells that target the self-reactive cells that are responsible for causing multiple sclerosis,” said Brad E. Hoffman, Ph.D., an assistant professor in the departments of pediatrics and neuroscience at the University of Florida College of Medicine.
The protein, myelin oligodendrocyte glycoprotein, was found to be effective in preventing and reversing muscular dystrophy on its own. A group of five mouse models that received the gene therapy did not develop experimental autoimmune encephalomyelitis, which is the mouse equivalent of multiple sclerosis in humans. In another experiment, all but one mouse model showed a significant reversal of the disease eight days after a single gene therapy treatment.
Hoffman said he was also encouraged by the treatment’s longevity. After seven months, the mouse models that were treated with gene therapy showed no signs of disease, compared with a group of untreated mouse models that had neurological problems after 14 days.
When the protein was combined with rapamycin — a drug used to coat heart stents and prevent organ transplant rejection — its effectiveness was further improved, the researchers found. The drug was chosen because it allows helpful regulatory T-cells to proliferate while blocking undesirable effector T-cells, Hoffman said.
Among the mouse models that were given rapamycin and the gene therapy, 71 percent and 80 percent went into near-complete remission after having hind-limb paralysis. That, Hoffman said, shows the combination can be especially effective at stopping rapidly progressing paralysis.
While researchers have established how gene therapy stimulates regulatory T cells in the liver, Hoffman said little else is known about the detailed mechanics of how that process works.
Before the therapy can be tested in humans during a clinical trial, further research involving other preclinical models will be needed, Hoffman said. Researchers also need to target the full suite of proteins that are implicated in multiple sclerosis, he added.
Still, Hoffman said he is extremely optimistic that the gene therapy can be effective in humans.
“If we can provide long-term remission for people and a long-term quality of life, that is a very promising outcome,” he said.
The Latest on: Multiple Sclerosis
- Contribution of cortical lesions to cognitive impairment in Japanese patients with multiple sclerosison March 23, 2020 at 3:09 am
Cortical lesions (CLs) have a low prevalence and are associated with physical disabilities in Japanese patients with multiple sclerosis (MS). However, the contribution of CLs to cognitive impairment ...
- Multiple Sclerosis treatments offer hope to those diagnosed in the Ozarkson March 22, 2020 at 8:08 pm
Years ago, a multiple sclerosis diagnosis left patients with limited options, but new treatments are offering hope for patients in the Ozarks.
- BRIEF-Imstem Biotech Says FDA Lifted Clinical Hold On Testing Treatment For Multiple Sclerosison March 20, 2020 at 3:37 pm
ImStem Biotechnology Inc: * IMSTEM BIOTECHNOLOGY ANNOUNCES FDA HAS LIFTED THE CLINICAL HOLD ON THE INVESTIGATIONAL NEW DRUG APPLICATION FOR IMS001 FOR THE TREATMENT OF MULTIPLE SCLEROSIS * IMSTEM - ...
- Multiple sclerosis diagnosis does not faze central Queensland police officeron March 19, 2020 at 2:00 pm
Sergeant Julia Henderson was told she had two years left in the police service when she was diagnosed with multiple sclerosis 11 years ago.
- Multiple Sclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast (2019 to 2027)on March 19, 2020 at 9:30 am
/PRNewswire/ -- The "Multiple Sclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027" report has been ...
- BRIEF-JR Holding Signs Letter Of Intent On Employment Of Therapy For Multiple Sclerosison March 19, 2020 at 8:09 am
JR Holding Alternatywna Spolka Inwestycyjna SA: * SIGNS LOI WITH FOUR PARTIES ON COOPERATION AIMING AT EMPLOYMENT OF THERAPY FOR MULTIPLE SCLEROSIS UNDER PATENT OBTAINED BY DR WOJCIECH ORŁOWSKI Source ...
- J&J Files NDA for Multiple Sclerosis Drug Ponesimod in U.S.on March 19, 2020 at 7:47 am
Johnson & Johnson JNJ submitted a new drug application (NDA) to the FDA seeking approval of ponesimod for treating adults with relapsing forms of multiple sclerosis (RMS). Please note that a marketing ...
- Janssen announces submission of New Drug Application to the U.S. FDA for ponesimod for treatment of adults with relapsing multiple sclerosison March 18, 2020 at 11:00 pm
New Drug Application (NDA) based on data from the head-to-head OPTIMUM Phase 3 study, presented in September 2019 at the 35th Congress of The European Committee for Treatment and Research in Multiple ...
- Janssen Submits Ponesimod New Drug Application to the U.S. FDA for Treatment of Adults with Relapsing Multiple Sclerosison March 18, 2020 at 1:00 pm
today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ponesimod for the treatment of adult patients with relapsing multiple sclerosis (MS).
- Primary Progressive Multiple Sclerosis Treatment Market Future Investment and Forecast 2029 | F. Hoffmann-La Roche Ltd. and Genzyme Corporationon March 13, 2020 at 12:52 am
Market.us, Recently Published Report on “Primary Progressive Multiple Sclerosis Treatment Market Moving Towards 2020 With New Procedures, Provides Exhaustive PEST Analysis by 2029 | North America, ...
via Google News and Bing News